ENLV - Company ID 0001596812
Enlivex Therapeutics Ltd. (ENLV) reported net income of $1.24B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $1.24B | +8329.2% |
| FY 2024 | -$15.01M | +48.3% |
| FY 2023 | -$29.07M | +6.4% |
| FY 2022 | -$31.06M | -114.7% |
| FY 2021 | -$14.47M | -22.4% |
| FY 2020 | -$11.82M | -26.0% |
| FY 2019 | -$9.38M | -121.2% |
| FY 2018 | -$4.24M | -69.4% |
| FY 2017 |
Enlivex Therapeutics Ltd. (ENLV) reported net income of $1.24B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Enlivex Therapeutics Ltd.'s net income grew from -$229.00K to $1.24B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$2.50M |
| +84.4% |
| FY 2016 | -$16.02M | -4.3% |
| FY 2015 | -$15.37M | -118.8% |
| FY 2014 | -$7.02M | -513.3% |
| FY 2013 | -$1.15M | -400.0% |
| FY 2012 | -$229.00K | - |